ORIC - oricpharma.com Trailing Twelve Months Revenue Growth

ORIC Pharmaceuticals revenues rely on investment inflows, as the company lacks commercial products. The LTM sales volume trend reflects current dynamics, where the actual level equals 0.00. The company develops molecules to combat tumor resistance. High future margins are possible following FDA approval, despite the current stage of intensive capital burn within R&D.

ORIC Pharmaceuticals - ORIC Sales Growth YoY (TTM) (period 02/11/2024 - 11/15/2026)

ORIC Pharmaceuticals, Inc. - analytical breakdowns and key metrics (ORIC)

- price and consensus price forecast:

Price Rate Chart ORIC Pharma|ORIC - Analyst Consensus Forecast

- market capitalization statistics:

Market Value ORIC Pharma|ORIC - Real Price to Acquire Entire Company

- book capitalization data:

Book Price of a Share ORIC Pharmaceuticals|ORIC - Book Capitalization|Market-to-Book Ratio oricpharma.com|ORIC - Company Total Assets

- company total debt and liquidity indicators:

Debt to Equity Ratio ORIC Pharmaceuticals|ORIC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ORIC Pharma|ORIC - Company Total Debt|Debt to Book Capital ORIC Pharmaceuticals, Inc.|ORIC - Company Long-Term Debts|Company Short-Term Loans and Borrowings ORIC Pharmaceuticals|Immediate Liquidity oricpharma.com

- financial results and valuation multiples details:

ORIC - Company Net Income|Expected Net Income ORIC Pharmaceuticals|ORIC - P/E Multiple|Forward P/E Multiple oricpharma.com|ORIC - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio ORIC Pharma|ORIC - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months ORIC Pharmaceuticals|ORIC - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months oricpharma.com|ORIC - Earnings per share growth in current year|Expected earnings per share trend next year ORIC Pharmaceuticals

- sales revenue and business income indicators:

ORIC - Revenue and Sales Volume|Company Future Sales ORIC Pharma|ORIC - P/S Multiple|Forward Price-to-Revenue Multiple ORIC Pharma|ORIC - Revenue Growth YoY (Last 12 Months)

Fundamental company valuation:ORIC Pharma ORIC

This indicator measures the rolling year revenue expansion rate, allowing for the rapid identification of market cycle phase shifts prior to official reports. For ORIC Pharmaceuticals (ORIC), the rolling year-over-year commercial revenue trend reflects the commercialization of molecules following FDA approval, where sales growth confirms the success of clinical trials and the effectiveness of combating cancer resistance.

Who ORIC Pharmaceuticals competes with

Revenue Growth Rate YoY (Last Twelve Months) Genmab US|Exelixis Inc - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvalent|KYMR (Kymera Therapeutics) - Revenue Growth YoY (Last 12 Months)|IDYA: Revenue Change YoY (Last 12 Months)|ELVN (enliventherapeutics.com) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Relay Pharma RLAY|Sales Growth YoY (TTM) NRIX|Tyra Biosciences - Sales Growth YoY (Last 12 Months)|Verastem - Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) GLUE|CGEM: Revenue Growth YoY (Last 12 Months)|Immuneering Inc. - Revenue Change YoY (Last 12 Months)|CCCC: Sales Growth YoY (TTM)|Black Diamond - Revenue Dynamics YoY (Last Twelve Months)|RPTX (Repare Therapeutics Inc) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth PMV Pharmaceuticals Inc. PMVP|Sales Growth YoY (Last Twelve Months) Karyopharm Therapeutics, Inc. (KPTI)|PPCB (Propanc Biopharma) - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BGMS (Cyclacel)|Sales Growth YoY (TTM) Aadi Bioscience AADI|ALRN - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth BPMC|GLYC (glycomimetics.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth SpringWorks Therapeutics, Inc (SWTX)